15581-80-3

Usage

Uses

Used in Chemical Synthesis:
Diisobutyraldehyde Disulfide is used as an intermediate in the synthesis of 2-Mercapto-2,2-dimethylethanol (M252700) for its ability to facilitate the formation of this important compound.
Used in Nano-Graphene Synthesis:
Diisobutyraldehyde Disulfide contributes to the synthesis of 2-Mercaptoethanol (M225480), which is a derivative used in the creation of nano-graphene. Nano-graphene is a valuable material for cellular imaging and drug delivery applications due to its unique properties.
Used in Polymeric Micelles Synthesis:
Diisobutyraldehyde Disulfide is also utilized in the synthesis of multifunctional polymeric micelles, which are essential in the specific targeting of tumor disruption. The compound plays a role in creating these micelles, which have potential applications in cancer treatment and therapy.

Upstream product

• 78-84-2 isobutyraldehyde 
• 590-86-3 isovaleraldehyde 
• 72647-51-9 2-Methyl-propanal-2-sulfenylchlorid 
• 108-98-5 thiophenol 

Downstream Products

• 54410-21-8 C₂₂H₂₄Br₂Cl₂N₂S₂ 
• 54410-23-0 C₂₄H₃₄N₄S₂ 
• 135937-76-7 1,2,3,6,7,8-hexahydro-3,3,6,6-tetramethyl-4,5,1,8-benzodithiadiazacyclodecine 
• 207386-70-7 6-(4-hydroxybenzyl)-3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodecane 
• 300765-96-2 6-(p-carbethoxybenzyl)-3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodeca-4,8-diene 
• 135937-92-7 N,N'-bis(2-mercapto-2-methylpropyl)-1,2-benzenediamine 
• 96929-53-2 2,9-DIMETHYL-2,9-DIMERCAPTO-5-(2-HYDROXYPHENYL)-4,7-DIAZADECANE 
• 96929-54-3 1-[2-(2-Mercapto-2-methyl-propylamino)-1-(2-methoxy-phenyl)-ethylamino]-2-methyl-propane-2-thiol 
• 1258542-50-5 N,N'-bis-(2-(4-methoxybenzylthio)-2-methylpropyl)propane-1,3-diamine 
• 131270-57-0 ([2-(4-Methoxy-benzylsulfanyl)-2-methyl-propyl]-{2-[2-(4-methoxy-benzylsulfanyl)-2-methyl-propylamino]-2-methyl-propyl}-amino)-acetic acid ethyl ester 
• 131270-56-9 [2-(4-Methoxy-benzylsulfanyl)-2-methyl-propyl]-{2-[2-(4-methoxy-benzylsulfanyl)-2-methyl-propylamino]-1,1-dimethyl-ethyl}-amine 
• 207386-71-8 [6-(4-tert-Butoxycarbonylmethoxy-benzyl)-8-tert-butoxycarbonylmethyl-3,3,10,10-tetramethyl-[1,2,5,8]dithiadiazecan-5-yl]-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodeca-4,8-diene

The synthesis of C10H18N2S2 was described. It was observed that the molecule of the compound possess a local twofold axis and the arrangement of the S2N2 donor atoms in the macrocycle is anticlinal. The cyclic structure of the given compound is in contrast with the linear structure of the diamine-dithiol compound obtained from a reduction reaction. It was found that the H atoms bonded to C atoms were positioned geometrically in the compound.

A Novel and Efficient Method for the Technetium-99m Labelling of Disulfide Compounds Using a Tetrahydroborate Exchange Resin

A novel and efficient method for the technetium-99m labelling of disulfide compound 7 was established with high radiochemical purity in which tetrahydroborate exchange resin (BER) simultaneously carries out the reduction of 7, the reduction of [99mTc]pertechnetate and chelation of 7 with technetium-99m. The labelling occurs in a one-pot three-step procedure that is amenable to the preparation of 99mTc-radiopharmaceuticals.

First examples of oxidizing aldehydes to carboxylic acids in the presence of a tertiary disulfide functional group: Synthesis of novel diacid-disulfides

The disulfide functionality exists in numerous organic compounds of interest in both chemistry and biology. In view of the fact that the disulfide function is highly susceptible to further oxidation by a broad range of agents, conducting a chemoselective

ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs) that target BRM for degradation, to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where BRM degradation is beneficial.

RADIOACTIVELY LABELED SUBSTANCE

Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.

Radioactively Labeled Substance

Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.

Nitrostated and nitrosylated prostaglandins, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

Tc-labeled arylpiperazine derivatives for imaging serotonin receptor

The present invention relates to Tc-labeled arylpiperazine derivatives for imaging serotonin receptor and, more particularly, to arylpiperazine derivatives coupled with MAMA-disulfide, N2S2 or dimethyl-N2S2 chel

SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.